Patient-Focused Drug Development (PFDD) is no longer a regulatory aspiration; it is an operational necessity.
Global regulators now expect structured, traceable, and meaningful patient input throughout clinical development. Yet for many pharmaceutical organizations, embedding PFDD across teams, regions, and programs remains complex and fragmented.
The question is no longer if you engage patients—but how effectively you do it.
